MANNKIND CORP Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
MANNKIND CORP (MNKD) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 0.00% for the 1-month period ending 2012-12-20, per its 10-K filed 2013-03-18.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2015-03-02
- 2012-12-20: Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 0 month 0.00%; Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 0.00%; Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 1 month 0.00%.
- 2012-10-18: Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 0 month 0.11%; Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 0.11%; Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 1 month 0.11%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 0 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 1 month |
|---|---|---|---|
| 2012-12-20 | 0.00% 10-K · filed 2014-03-03 | 0.00% 10-K · filed 2015-03-02 | 0.00% 10-K · filed 2013-03-18 |
| 2012-10-18 | 0.11% 10-K · filed 2014-03-03 | 0.11% 10-K · filed 2015-03-02 | 0.11% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |